Autopsy report · NCT03110549
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
Cause of deathRegulatory or ethics
“Drug development suspended by current holder of IND”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 2 years 8 months before it stopped.
- 9 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- TaiMed Biologics Inc.
- Sponsor type
- Industry
- Conditions
- Human Immunodeficiency Virus
- Interventions
- TMB-607; Placebo
- Participants
- 9
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
“Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the study drug development” - Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
“Sponsor suspended development of the drug on September 3, 2008.” - Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
“Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.” - Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
“The IND has been withdrawn from FDA” - Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
“Drug development stopped”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.